Company intelligence / Profile preview

Amphera B.V.

's-Hertogenbosch, 's-Hertogenbosch , Noord-Brabant, Netherlandsamphera.nl ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

Amphera’s lead product MesoPher has completed a randomized phase II/III trial in pleural mesothelioma. While the primary endpoint was not met for all patients, clinically meaningful benefit was observed in a significant subgroup with stable disease after chemotherapy. The therapy demonstrated an excellent safety profile and induced broad immune responses. Positive results have also been reported from a phase II study in resected pancreatic cancer.

Therapeutic areas: Oncology
Modalities: Dendritic cell therapyTherapeutic vaccines (autologous dendritic cells loaded with tumor lysate)
Industry: Biotech

Drug pipeline

3 assets

MesoPher

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Amphera B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amphera B.V..

Explore the full profile